Stay at the forefront of the week’s champions and runners-up among publicly traded biotech companies and the reasons behind the ups or downs of their stock price fluctuations.
Biogen (BIIB)’s second cost-cutting restructuring in five months . . .
The post StockWatch: Investors Unfazed by Biogen CEO Search, Aduhelm Cutbacks appeared first on GEN – Genetic Engineering and Biotechnology News.